deltatrials
Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06615908

Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy (PatACT)

A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial

Sponsor: University of British Columbia

Interventions Psilocybin
Updated 4 times since 2024 Last updated: Dec 22, 2025 Started: May 27, 2025 Primary completion: Oct 30, 2026 Completion: Mar 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06615908, this PHASE1 trial focuses on Persisting Symptoms After Concussion and remains actively recruiting participants. Sponsored by University of British Columbia, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2024 – ~May 2025 · 7 months · monthly snapshotNot Yet Recruiting~May 2025 – ~Oct 2025 · 5 months · monthly snapshotNot Yet Recruiting~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshotRecruiting~Jan 2026 – present · 6 months · monthly snapshotRecruiting

Change History

4 versions recorded
  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1

  2. Oct 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

    Status: Not Yet RecruitingRecruiting

  3. May 2025 — Oct 2025 [monthly]

    Not Yet Recruiting PHASE1

  4. Oct 2024 — May 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of British Columbia
  • University of Calgary
Data source: University of Calgary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations